Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study-Reference-Cited by-同舟云学术

Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study

Published:2022-07-14 Issue:12 Volume:57 Page:1435-1442
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Hellström Per M.¹^ORCID,Gemmen Eric²,Ward Heather A.²,Koo Hyewon³,Faccin Freddy⁴,Xue Zhenyi⁵,Malmborg Petter⁶

Affiliation:

1. Department of Medical Sciences, Uppsala University, Uppsala, Sweden

2. Epidemiology & Outcomes Research, IQVIA Real World Solutions, Cambridge, MA, USA

3. Global Database Studies, Real World Solutions, IQVIA Solutions AB, Arenastaden, Sweden

4. GMA Biotherapeutics, AbbVie Inc, San Juan, Puerto Rico

5. Global Medical Affairs Statistics, Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, USA

6. Department of Clinical Science and Education, Karolinska Institute, Stockholm, Sweden

Funder

AbbVie

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2022.2090275

Reference33 articles.

1. Inflammatory Bowel Disease

2. An Overview of Inflammatory Bowel Disease Unclassified in Children

3. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

4. Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General Population

5. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

2. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study;Digestive and Liver Disease;2024-01

3. Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627;Current Medical Research and Opinion;2022-11-07